MedTrace Logo

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 318

Last updated 2015-12-23

No results posted yet for this study

Summary

The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidogrel therapy.

Conditions

  • Percutaneous Coronary Intervention
  • Dual Antiplatelet Therapy
  • Aspirin
  • Clopidogrel

Sponsors & Collaborators

Principal Investigators

  • George Dangas, MD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01582217 on ClinicalTrials.gov